TearLab Corp fka TEAR

[ash111]

TEAR interesting coverage forecast sales of $145m on only a modest market penetration. Edison 14 May 2015 : "If it can achieve even modest market penetration it may reach potential yearly card sales of $145m. This assumes 10% provider penetration, 25 patients per day, 25% of patients tested and 175 clinic days per year".

Edison also said that "The current EV of $73.4m", "May not reflect market potential". Cutrent EV is only $10m, extremely undervalued relating EV mentioned.

TEAR Security Details
Share Structure
Market Value1 $9,934,444
a/o Oct 06, 2017

This coverage was written exactly 2 years ago before TEAR Achieved those Milestones (Achieved more than a modest market penetration as Edison forecasted):

1. Approval in the Republic of Korea by the Ministry of Health and Welfare

2. Commercial launch in the Republic of India

3. A/o May 12, 2017- approval in the Federative Republic of Brazil (the largest market in Latin America with a population of over 200 million).
CEO of TearLab Corporation said, "We are pleased to complete these major milestones for TearLab’s international business as we continue to increase our global footprint in key strategic markets. Due to their size and growing dry eye populations, these three markets represent significant opportunity for us to expand our business and continue toward our goal of making osmolarity testing a global standard of care in diagnosing dry eye disease.”

4. CE Mark.

Strong IP Portfolio:

U.S. 11 Issued Patents
ROW 25 Issued Patents
Pending 18 Patents

TearLab Corporation currently has a consensus rating of “Buy” and a consensus price target of $4.90.

https://www.thestockobserver.com/2017/10/06/tearlab-corporation-tear-sees-unusually-high-trading-volume.html/amp

DD: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=135132249

Oct 7-11,2017 Lisbon, European Society of Cataract and Refractive Surgeons (ESCRS), Tearlab will display its new Discovery Systems.